Rollout

The communication of drug information is tightly guarded by the Food and Drug Administration (FDA) and represents a very complicated set of rules that govern each communication type. Different guidelines govern communications with consumers vs. clinicians. What the venue is will determine whether the rules for on-label vs. off-label communications apply.

During the first months of the roll out of a new drug, direct to consumer advertising (DTC) is not permitted. This is the time when the clinicians are to be educated about when to use the drug, how it works, side effects, and more. This allows for a more managed roll out of the drugs to patients. It is designed to avoid an onslaught of patients demanding the newly advertised miracle cure when a physician has no familiarity with the drug.

Traditionally, reaching physicians has been accomplished by holding dinner meetings at a local venue with a notable key opinion leader from that drug area to talk about the drug; it can be a CME event. This approach has serious limitations. It's very costly, on average, we estimate about $ 500 per attendee.

Getting clinicians to attend is very difficult. They have very busy schedules and want to spend evenings with family. Physicians want options that fit into their schedules and they want high profile speakers. MedRespond's solution gives them both by allowing them 24/7 access and featuring key opinion leaders who will share their insights.

MedRespond has a Pharma detailing template that brings the traditional 'Drug Fact Sheet' and insert to life. The FDA is very specific about what information must be conveyed and has provided a fixed format for this. MedRespond's DrugFactSite is an online version of this information, in a compatible format that enables physicians and patients to explore the meaning of the information presented. There are two designs - one to convey they information to clinicians and one to convey this information to consumers.